10X Genomics (TXG)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
At a market value of $11.7B, 10X Genomics's free cash flow of $130M (fiscal 2025) would need to grow about 25% a year for the stock to be worth today's price.
Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from 10X Genomics's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.
Fundamental grade
Five factors scored 1 to 9 from TXG's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from 10X Genomics's 10-K filings. The deep dive has 15+ years, quarters and every line.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $490M | $516M | $619M | $611M | $643M |
| Net income | -$58M | -$166M | -$255M | -$183M | -$44M |
| Free cash flow | -$123M | -$165M | -$64M | -$6M | $130M |
| EPS (diluted) | -$0.53 | -$1.46 | -$2.18 | -$1.52 | -$0.35 |
| Operating margin | -10.7% | -32.5% | -42.9% | -31.9% | -9.5% |
Where the revenue comes from
Revenue by products, fiscal 2025.
Superinvestors who own TXG
From each investor's latest 13F filing (what a 13F shows). 3 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Cliff Asness AQR Capital Management |
Trimmed | $75M | 0.03% | Q2 2026 |
| Stanley Druckenmiller Duquesne Family Office |
New position | $15M | 0.30% | Q2 2026 |
| Joel Greenblatt Gotham Asset Management |
Trimmed | $4M | 0.01% | Q2 2026 |
Insider buying
Open-market purchases by 10X Genomics's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when TXG trades at or below it.
Free accounts get 3 price alerts. No card needed.
In the full deep dive
Questions
What growth does 10X Genomics's stock price imply?
At a market value of $11.7B, 10X Genomics would need its free cash flow to grow about 25% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price.
Are 10X Genomics insiders buying the stock?
No open-market insider purchases of TXG in the last 12 months, according to SEC Form 4 filings.
Which superinvestors own 10X Genomics?
3 of the superinvestors Investingly tracks hold TXG in their latest 13F, including Cliff Asness, Stanley Druckenmiller, Joel Greenblatt.
Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.